Detalhe da pesquisa
1.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
N Engl J Med
; 389(6): 514-526, 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366315
2.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
N Engl J Med
; 389(10): 877-888, 2023 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351564
3.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet
; 402(10401): 529-544, 2023 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385280
4.
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Lancet
; 402(10400): 472-483, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369232
5.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Lancet
; 400(10366): 1869-1881, 2022 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36354040
6.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes Obes Metab
; 25(9): 2642-2649, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37264711
7.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Diabetes Obes Metab
; 25(9): 2634-2641, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344954
8.
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.
Diabetes Obes Metab
; 25(4): 1080-1090, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541037
9.
Synthesis, Reactivity and Structural Properties of Trifluoromethylphosphoranides.
Chemistry
; 28(14): e202104308, 2022 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35025112
10.
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Diabetes Obes Metab
; 24(1): 148-153, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34542221
11.
A Versatile Silver(I) Pentafluorooxosulfate Reagent for the Synthesis of OSF5 Compounds.
Angew Chem Int Ed Engl
; 60(33): 17866-17870, 2021 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34165887
12.
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(12): 2451-2459, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462955
13.
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Diabetes Obes Metab
; 22(10): 1886-1891, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32519795
14.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes Metab
; 22(6): 938-946, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31984598
15.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Lancet
; 392(10160): 2180-2193, 2018 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30293770
16.
Corannulenes with Electron-Withdrawing Substituents: Synthetic Approaches and Resulting Structural and Electronic Properties.
Chemistry
; 25(14): 3440-3454, 2019 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30238526
17.
Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
Diabetes Obes Metab
; 21(11): 2570-2575, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31364266
18.
Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
Diabetes Obes Metab
; 26(2): 785-789, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37989596
19.
Selective Synthesis of Perfluoroalkylated Corannulenes and Investigation of their Structural, Dynamic and Electrochemical Behavior.
Chemistry
; 24(42): 10756-10765, 2018 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29691932
20.
Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
Diabetes Obes Metab
; 20(8): 2023-2028, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603872